Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…arms (n=8,684 patients) with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult soli…
…8.9% were male and 51.1% were female. The most common ICIs were Pembrolizumab (16276, 45.38%), Nivolumab (10548, 29.41%), Ipilimumab (3120, 8…
…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…
… TNBC (ER-/PR-/HER2-) who received at least one dose of an ICI (pembrolizumab, atezolizumab, nivolumab, or durvalumab) between 2014 and 2025.…
…iota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: preliminary …
…d neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, p…
…05755Thomas SS, Gogas H, Hong YK, et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and …
…) or unknown (30.8%, 53.8%). The most common ICI agent used was pembrolizumab (92.3%), with 7 patients receiving ICI as a first-line systemic…
…r model.Results The expression constructs for pembrolizumab and nivolumab demonstrated dose-dependent expression in vitro. The PD-1/PD-L1…
…ve biomarker in patients with aUC commencing EV with or without pembrolizumab.Methods We conducted a multicenter, retrospective real-world an…
…linded), vibo/pembro alone (arm 2; open label), or placebo plus docetaxel (arm 3; blinded). PD-L1 expression was assessed using PD-L1 IHC…
…tribution of immune and tumor cells in the TME as a response to ZM008 treatment. Key inclusion criteria: histologically confirmed adv…